Evidence insufficient for assessing benefits and harms of screening for children and adolescents<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Sept. 13, 2022 (HealthDay News) — The U.S. Preventive Services Task Force (USPSTF) concludes that evidence is insufficient to recommend for or against screening children or adolescents for prediabetes or type 2 diabetes. These findings form the basis of a final recommendation statement published in the Sept. 13 issue of the Journal of the American Medical Association<\/em>.<\/p>\n Daniel E. Jonas, M.D., M.P.H., from RTI International-University of North Carolina at Chapel Hill Evidence-based Practice Center, and colleagues reviewed the evidence on the benefits and harms of screening children and adolescents for prediabetes and type 2 diabetes. Data were included from eight publications, with 856 participants; six publications were from the Treatment Options for Type 2 Diabetes in Adolescents and Youth study. The researchers found that none of the studies directly examined the benefits or harms of screening.<\/p>\n Based on these findings, the USPSTF concludes that the evidence is insufficient for assessing the benefits and harms of type 2 diabetes screening in children and adolescents (I statement).<\/p>\n “The rate of prediabetes and type 2 diabetes in youth is increasing,” a task force member said in a statement. “It is important that health care professionals be aware of the signs and symptoms of prediabetes and type 2 diabetes and use their judgment when determining whether or not to screen youth.”<\/p>\n Evidence Report<\/a><\/p>\n Final Recommendation Statement<\/a><\/p>\n